Adrenomyeloneuropathy - A Pipeline Analysis Report

Overview of the drug development pipeline for adrenomyeloneuropathy

Adrenoleukodystrophy is a genetic disease that affects the adrenal glands and the nervous system. There are three forms of adrenoleukodystrophy, namely cerebral adrenoleukodystrophy, adrenomyeloneuropathy, and adrenal-insufficiency-only-type. The disease can develop lesions in the brain, which leads to behavioral symptoms. Adrenomyeloneuropathy is the adult onset of adrenoleukodystrophy. The mutation in the ABCD1 gene can lead to adrenomyeloneuropathy, which affects the spinal cord. It also leads to behavioral abnormalities, vision loss, and hearing problems. Males are more vulnerable to adrenomyeloneuropathy than females. The mean age for the onset of adrenomyeloneuropathy is 28-60 years. With rising incidences of the disease, the need for drug development for adrenomyeloneuropathy has increased considerably in the recent years.

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for adrenoleukodystrophy. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of drug molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of adrenomyeloneuropathy. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• AGTC
• DeuteRx
• Magneta Therapeutics
• Minoryx Therapeutics
• NeuroVia

Therapeutic assessment of the drug development pipeline for adrenomyeloneuropathy by route of administration

• Intravenous
• Oral

The intravenous route of administration (ROA) involves the application of the drug directly into the veins, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for adrenomyeloneuropathy by therapy

• Monotherapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for adrenomyeloneuropathy are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for adrenomyeloneuropathy?
• What are the companies that are currently involved in the development of drug molecules for adrenomyeloneuropathy?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.